Literature DB >> 25119827

An investigation into the relationship between anti-Helicobacter pylori and anti-Saccharomyces cerevisiae antibodies in patients with axial spondyloarthritis and Crohn disease.

Igor Kunze Rodrigues1, Michele Andrigueti, Ione Dilma de Oliveira Gil, Leonardo de Lucca Schiavon, Kenia Rodrigues de Andrade, Ivanio Alves Pereira, Gláucio Ricardo Werner de Castro, Adriana Fontes Zimmermann, Luciano Nascimento Saporiti, Maria Luiza Bazzo, Fabricio Souza Neves.   

Abstract

Spondyloarthritis (SpA) is a musculoskeletal inflammatory disease linked with immune responses to intestinal microbiota, and subclinical intestinal ulcerations that are closely related to inflammatory bowel diseases. Helicobacter pylori is a common cause of gastroduodenal ulceration, and anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with intestinal inflammation in both Crohn disease (CD) and SpA. We investigated the relationship between H. pylori and ASCA. Ninety-one patients with axial SpA and forty with CD were included. ASCA IgG/IgA and anti-H. pylori IgG titers were assessed by ELISA. The proportion of ASCA+ patients in the positive and negative anti-H. pylori IgG groups with SpA and CD were compared using Chi-square tests, and correlations were evaluated using the Spearman's coefficient. Anti-H. pylori IgG titers were significantly negatively correlated with the ASCA IgG (r = -0.563, p < 0.001) and IgA (r = -0.342, p = 0.019) titers in the axial SpA patients. The same pattern of negative correlation was also observed in the CD patients. Anti-H. pylori+ serology was significantly more frequent in axial SpA patients than in those with CD (52.4 vs. 18.4 %, p < 0.001), while ASCA+ serology was significantly more frequent in CD patients than in SpA patients. A negative correlation between the anti-H. pylori titers and ASCA was found for axial SpA and CD. Anti-H. pylori+ serology was more frequent in SpA than in CD, while ASCA positivity was more frequent in CD patients than in those with SpA. A possible influence of H. pylori on the development of ASCA needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25119827     DOI: 10.1007/s00296-014-3088-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  A historical perspective of the spondyloarthritis.

Authors:  Henning Zeidler; Andrei Calin; Bernard Amor
Journal:  Curr Opin Rheumatol       Date:  2011-07       Impact factor: 5.006

2.  Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.

Authors:  Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers
Journal:  Gut       Date:  2012-05       Impact factor: 23.059

Review 3.  Clinical practice. Helicobacter pylori infection.

Authors:  Kenneth E L McColl
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

4.  DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection.

Authors:  Mathias Oertli; Malin Sundquist; Iris Hitzler; Daniela B Engler; Isabelle C Arnold; Sebastian Reuter; Joachim Maxeiner; Malin Hansson; Christian Taube; Marianne Quiding-Järbrink; Anne Müller
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

5.  Seroprevalence of Helicobacter pylori infection in inflammatory bowel disease: is Helicobacter pylori infection a protective factor?

Authors:  P O Väre; B Heikius; J A Silvennoinen; R Karttunen; S E Niemelä; J K Lehtola; T J Karttunen
Journal:  Scand J Gastroenterol       Date:  2001-12       Impact factor: 2.423

6.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

7.  Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis.

Authors:  Debby Laukens; Michel Georges; Cécile Libioulle; Cynthia Sandor; Myriam Mni; Bert Vander Cruyssen; Harald Peeters; Dirk Elewaut; Martine De Vos
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

8.  Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment.

Authors:  S Z Aydin; P Atagunduz; M Temel; M Bicakcigil; D Tasan; H Direskeneli
Journal:  Rheumatology (Oxford)       Date:  2007-12-26       Impact factor: 7.580

9.  Role of seroconversion in confirming cure of Helicobacter pylori infection.

Authors:  M Feldman; B Cryer; E Lee; W L Peterson
Journal:  JAMA       Date:  1998 Jul 22-29       Impact factor: 56.272

10.  Helicobacter pylori-infection status and childhood living conditions are associated with signs of allergic diseases in an occupational population.

Authors:  Petra Ina Pfefferle; Alexander Krämer
Journal:  Eur J Epidemiol       Date:  2008-08-14       Impact factor: 8.082

View more
  3 in total

1.  A positive Helicobacter pylori test is associated with low spondylarthritis incidence in a Danish historical cohort study.

Authors:  Lars E Bartels; Alma B Pedersen; Nickolaj R Kristensen; Hendrik Vilstrup; Kristian Stengaard-Pedersen; Jens F Dahlerup
Journal:  Rheumatol Int       Date:  2019-12-04       Impact factor: 2.631

Review 2.  A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis.

Authors:  Lianjun Yang; Liping Wang; Xin Wang; Cory J Xian; Hai Lu
Journal:  Int J Mol Sci       Date:  2016-12-17       Impact factor: 5.923

Review 3.  Putative Pathobionts in HLA-B27-Associated Spondyloarthropathy.

Authors:  Tejpal Gill; James T Rosenbaum
Journal:  Front Immunol       Date:  2021-01-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.